The Department of Defense is offering the Prostate Cancer Lab-Clinical Transition Award to support innovative preclinical studies on lead agents or medical devices with the potential to advance prostate cancer clinical care. Applicants must provide validated targets, access to lead agents, and mechanism of action. Preliminary data demonstrating target availability and efficacy in relevant tissues is required. Research from preclinical studies to cGMP production is supported. The closing date for applications is August 23, 2012.
Opportunity ID: 156514
General Information
| Document Type:: | Grants Notice |
| Funding Opportunity Number:: | W81XWH-12-PCRP-LCTA |
| Funding Opportunity Title:: | DoD Prostate Cancer Laboratory-Clinical Transition Award |
| Opportunity Category:: | Discretionary |
| Opportunity Category Explanation:: | |
| Funding Instrument Type:: | |
| Category of Funding Activity:: | Science and Technology and other Research and Development |
| Category Explanation:: | |
| Expected Number of Awards:: | 2 |
| Assistance Listings Number(s):: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement:: | No |
| Version:: | Synopsis 1 |
| Posted Date:: | Mar 20, 2012 |
| Last Updated Date:: | |
| Original Closing Date for Applications:: | Aug 23, 2012 |
| Current Closing Date for Applications:: | Aug 23, 2012 |
| Archive Date:: | Sep 22, 2012 |
| Estimated Total Program Funding:: | $ 4,800,000 |
| Award Ceiling:: | $0 |
| Award Floor:: | $0 |
Eligibility
| Eligible Applicants:: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility:: |
Additional Information
| Agency Name:: | Dept. of the Army — USAMRAA |
| Description:: | Supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. For lead agents, PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agents mechanism of action. For lead agents, preliminary data should demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans. For medical devices preliminary data should demonstrate reliability, reproducibility and effectiveness for the medical device. Supports research that ranges from preclinical study through cGMP production. |
| Link to Additional Information:: | |
| Grantor Contact Information:: | If you have difficulty accessing the full announcement electronically, please contact: |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Synopsis 1 |
Package Status
Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:
Package No: 1
| Assistance Listings: | 12.420 |
| Competition ID: | |
| Competition Title: | |
| Opportunity Package ID: | PKG00108890 |
| Opening Date: | Mar 20, 2012 |
| Closing Date: | Aug 23, 2012 |
| Agency Contact Information:: | CDMRP Help Desk: 301-682-5507 |
| Who Can Apply:: | Organization Applicants |
| mendatory_forms |
SF424 (R & R) [V1.2] Project/Performance Site Location(s) [V1.4] Research & Related Budget [V1.1] Research And Related Senior/Key Person Profile (Expanded) [V1.2] Attachments [V1.1] |
| optional_forms | R & R Subaward Budget Attachment(s) Form 5 YR 30 ATT [V1.2] |
Packages
| Assistance Listings | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions | Who Can Apply: | |
|---|---|---|---|---|---|---|---|---|
| 12.420 | PKG00108890 | Mar 20, 2012 | Aug 23, 2012 | View | CDMRP Help Desk: 301-682-5507 | Organization Applicants |